Surveillance and Monitoring for ART Toxicities (SMARTT)
The SMARTT cohort includes Human Immunodeficiency Virus (HIV) exposed but uninfected infants and children at 22 clinical sites in the United States of America across 13 states and territories namely Alabame, California, Colorado, Florida, Ilinois, Louisiana, Maryland, New Jersey, New York, Pennsylvania, Tennessee, Texas, and Puerto Rico. Study visits are conducted annually for 5 years and then every other year. The cohort also includes a comparison group of 239 HIV-unexposed and uninfected children of similar sociodemographic background enrolled at 1, 3, 5, or 9 years of age. These participants had a single evaluation and were not followed longitudinally.
Study design
Cohort - open, Cohort - primary caregiver and child
Number of participants at first data collection
9,060 (participants as of 2025)
Recruitment is ongoing
Age at first data collection
0 - 12 years (participants)
Participant year of birth
Varied (participants)
Participant sex
All
Representative sample at baseline?
No
Sample features
Countries
Year of first data collection
2007
Primary Institutions
Harvard University
Profile paper DOI
Funders
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
National Heart, Lung, and Blood Institute (NHLBI)
National Institute of Allergy and Infectious Diseases (NIAID)
National Institute of Dental and Craniofacial Research (NIDCR)
National Institute of Mental Health (NIMH)
Ongoing?
Yes
Data types collected
- Computer, paper or task testing (e.g. cognitive testing, theory of mind doll task, attention computer tasks)
- Physical or biological assessment (e.g. blood, saliva, gait, grip strength, anthropometry)
- Secondary data
- Self-report questionnaire – paper or computer assisted
- None
- None
- Healthcare data
Engagement
Keywords
Consortia and dataset groups
